Company intelligence / Profile preview

ChanRx

Cleveland, Ohio, United States

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Vanoxerine showed promising Phase 2 results with >75% conversion to normal sinus rhythm and no ventricular tachycardia, but Phase 3 trial (Restore SR) was halted due to unidentified safety signals, leading to company shutdown in 2015.[3][5]

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

vanoxerine

Beyond the preview

Go deeper on ChanRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChanRx.

Explore the full profile